Low/Intermediate PCa Video Chat, Nov 11, 2024

by | Nov 12, 2024 | Active Surveillance PCa, Cancer Resources, High Risk/Recurrent/Advanced Prostate Cancer, Low/Intermediate Prostate Cancer

Low/Intermediate PCa

Low/Intermediate PCa Video Chat, Nov 11, 2024

Low/Intermediate PCa Video Chat, Nov 11, 2024

Ancan would like your input on its future planning and academic research. Please take a few minutes to complete The 2024 AnCan Survey which is at this link. 

AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostics.

WELCOME all to our newly recorded Low/Intermediate Prostate Cancer Group. To receive notice when new recordings are posted, either follow us on this YouTube Channel or sign up to our Blog via https://ancan.org/contact-us/ – check New Blog box.

Join our other free and drop in groups:
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
AnCan’s Prostate Cancer Forum is back (https://ancan.org/forums). If you’d like to comment on anything you see in our Recordings or read in our Reminders, just sign up and go right ahead. You can also click on the Forum icon at the top right of the webpage.
All AnCan’s groups are free and drop-in … join us in person sometime!

Editor’s Pick: Prognostic tools are a good starting point for discussing treatment options with your doctors. (bj)

Topics Discussed

Online resources to compare multiple prognostic tools (e.g., nomograms, PSMA, NCCN) to diagnose our disease; initial considerations for treatment decisions, such as: some urologists view younger men as better candidates for surgery — be careful of this bias when considering your treatment options; PROSTOX saliva swab for germline DNA testing and avoiding toxicity from radiation therapy; getting the right information so you can make an informed decision; post SBRT urination problems include: frequency, urgency, and discomfort (burning, stinging, tingling); clarification on SBRT (a treatment) and Meridian (a radiation machine); urgency and incontinence; active surveillance; RTIRE trial acceptance; AnCan survey emailed to you — let us know what you think; a little humor with emotional support llamas; Happy Veterans Day.

Chat Log

John A
https://www.mskcc.org/search#q=prostate%20cancer%20nomogram&t=All&sort=relevancy

Boykin Jordan
NCCN Guidelines for Prostrate Cancer
https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459

Boykin Jordan
PROSTOX
https://miradx.com/prostox

AnCan  – rick
Ming Zhou, MD, PhD | Mount Sinai, NYC  https://profiles.mountsinai.org/ming-zhou  Contact to find address for 2nd opinion.

Boykin Jordan
Artera
https://artera.ai/for-patients

Boykin Jordan
RTIRE Trial
https://www.primrmed.com/cancer-clinical-trials/rtire-trial

Eric- Atlanta
I received it! Just bad timing before the weekend.

Jim Stewart   Reno, NV
Good night everyone, grandson duty!!